Status:
COMPLETED
A Trial to Assess the Antipsychotic Efficacy of ITI-007
Lead Sponsor:
Intra-Cellular Therapies, Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Eligibility Criteria
Inclusion
- male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
- experiencing an acute exacerbation of psychosis
Exclusion
- any subject unable to provide informed consent
- any female subject who is pregnant or breast-feeding
- any subject judged to be medically inappropriate for study participation
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT02282761
Start Date
November 1 2014
End Date
September 1 2015
Last Update
October 2 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Site
Little Rock, Arkansas, United States
2
Clinical Site
Springdale, Arkansas, United States
3
Clinical Site
Escondido, California, United States
4
Clinical Site
Garden Grove, California, United States